Orchid Cellmark

LabCorp will purchase 30.5 million outstanding shares of Orchid Cellmark, including options, at $2.80 per share.

Revenue increase in the quarter was driven by strong growth in its UK business, which offset softness in the US.

Orchid Cellmark said that it believes revenue over the life of the award could total $5.6 million.

The company's UK business rose 44 percent year over year, while its US business receded 13 percent.

The contracts are for five UK police forces and are worth about $1.2 million.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The contracts are now set to expire in 2013 and have a combined value of about $10 million.

A 32 percent jump in its UK business offset a 17 percent decrease in US revenues.

The company's sales boost in the UK was offset by a 25 percent drop in US service revenue, which it attributed to tight state budgets' impact on forensic and paternity test sales.

People in the News


Stratos names former Roche CEO Dreismann to board; WaferGen appoints Lankard as SVP of worldwide sales; Dalziel joins Orchid Cellmark board


An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.